SG11201703366RA - Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development - Google Patents
Methods and compositions for recombinant dengue viruses for vaccine and diagnostic developmentInfo
- Publication number
- SG11201703366RA SG11201703366RA SG11201703366RA SG11201703366RA SG11201703366RA SG 11201703366R A SG11201703366R A SG 11201703366RA SG 11201703366R A SG11201703366R A SG 11201703366RA SG 11201703366R A SG11201703366R A SG 11201703366RA SG 11201703366R A SG11201703366R A SG 11201703366RA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccine
- compositions
- methods
- dengue viruses
- recombinant dengue
- Prior art date
Links
- 241000710829 Dengue virus group Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074053P | 2014-11-02 | 2014-11-02 | |
PCT/US2015/058610 WO2016070178A1 (en) | 2014-11-02 | 2015-11-02 | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703366RA true SG11201703366RA (en) | 2017-05-30 |
Family
ID=55858450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703366RA SG11201703366RA (en) | 2014-11-02 | 2015-11-02 | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
Country Status (12)
Country | Link |
---|---|
US (2) | US10398768B2 (ja) |
EP (1) | EP3212672A4 (ja) |
JP (1) | JP6671364B2 (ja) |
KR (1) | KR20170075775A (ja) |
CN (1) | CN107207619A (ja) |
AU (1) | AU2015338859A1 (ja) |
BR (1) | BR112017008952A2 (ja) |
CA (1) | CA2966198A1 (ja) |
MX (1) | MX2017005524A (ja) |
MY (1) | MY179251A (ja) |
SG (1) | SG11201703366RA (ja) |
WO (1) | WO2016070178A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017305313A1 (en) | 2016-08-01 | 2019-02-07 | Inbios International, Inc. | Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens |
CN106632620B (zh) * | 2016-11-29 | 2019-08-23 | 菲鹏生物股份有限公司 | 登革病毒重组抗原及其制备方法和应用 |
EP3606552A4 (en) * | 2017-04-07 | 2020-08-05 | The Rockefeller University | COMPOSITIONS AND PROCEDURES RELATED TO HUMAN NEUTRALIZING ANTIBODIES AGAINST ZIKA AND DENGUE-1 VIRUS |
CN110568190A (zh) * | 2019-08-30 | 2019-12-13 | 深圳国际旅行卫生保健中心 | 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法 |
US20230018080A1 (en) * | 2019-11-20 | 2023-01-19 | The University Of North Carolina At Chapel Hill | Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development |
WO2023178310A1 (en) * | 2022-03-17 | 2023-09-21 | The University Of North Carolina At Chapel Hill | Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same |
CN116716322B (zh) * | 2023-05-12 | 2024-05-31 | 中山大学 | 一种denv-3全长感染性克隆及其构建方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
EP1773403B1 (en) | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Alphavirus-based adjuvants |
DK2589602T3 (en) * | 2006-08-15 | 2016-07-25 | The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of | Development of dengue virus vaccine components |
EP2834265A4 (en) * | 2012-04-02 | 2015-10-14 | Univ North Carolina | METHODS AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES |
MX365957B (es) * | 2013-06-26 | 2019-06-20 | Univ North Carolina Chapel Hill | Métodos y composiciones para vacunas del virus del dengue. |
-
2015
- 2015-11-02 SG SG11201703366RA patent/SG11201703366RA/en unknown
- 2015-11-02 WO PCT/US2015/058610 patent/WO2016070178A1/en active Application Filing
- 2015-11-02 CA CA2966198A patent/CA2966198A1/en not_active Abandoned
- 2015-11-02 KR KR1020177014337A patent/KR20170075775A/ko unknown
- 2015-11-02 MX MX2017005524A patent/MX2017005524A/es unknown
- 2015-11-02 JP JP2017523804A patent/JP6671364B2/ja not_active Expired - Fee Related
- 2015-11-02 US US15/523,899 patent/US10398768B2/en not_active Expired - Fee Related
- 2015-11-02 MY MYPI2017701472A patent/MY179251A/en unknown
- 2015-11-02 AU AU2015338859A patent/AU2015338859A1/en not_active Abandoned
- 2015-11-02 EP EP15854399.1A patent/EP3212672A4/en not_active Withdrawn
- 2015-11-02 CN CN201580072021.7A patent/CN107207619A/zh active Pending
- 2015-11-02 BR BR112017008952A patent/BR112017008952A2/pt not_active Application Discontinuation
-
2019
- 2019-08-29 US US16/555,912 patent/US20200230224A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2017005524A (es) | 2018-01-26 |
AU2015338859A1 (en) | 2017-06-01 |
JP6671364B2 (ja) | 2020-03-25 |
EP3212672A4 (en) | 2018-04-25 |
US20200230224A1 (en) | 2020-07-23 |
EP3212672A1 (en) | 2017-09-06 |
BR112017008952A2 (pt) | 2018-01-16 |
WO2016070178A1 (en) | 2016-05-06 |
MY179251A (en) | 2020-11-02 |
US20170333548A1 (en) | 2017-11-23 |
KR20170075775A (ko) | 2017-07-03 |
JP2018500878A (ja) | 2018-01-18 |
US10398768B2 (en) | 2019-09-03 |
CN107207619A (zh) | 2017-09-26 |
CA2966198A1 (en) | 2016-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257410A1 (zh) | 逃避抗體的病毒載體的方法和組合物 | |
HK1243463A1 (zh) | 檢測rna病毒的組合物和方法 | |
ZA201700952B (en) | Indoles for use in influenza virus infection | |
IL266234A (en) | A new tilapia virus and its uses | |
SG11201606624WA (en) | Antibody moleules to dengue virus and uses thereof | |
SG11201703366RA (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
SG11201701256RA (en) | Vaccine compositions against dengue virus diseases | |
SG11201702116VA (en) | Viral rna segments as immunomodulatory agents and vaccine components | |
IL248223A0 (en) | Compositions of vaccine | |
HK1258584A1 (zh) | 用於製備減毒四價登革熱疫苗的方法 | |
EP3166637A4 (en) | Compositions and methods for treating dengue virus infection | |
SG11201701669PA (en) | Flavivirus virus like particle | |
SG11201510617WA (en) | Methods and compositions for dengue virus vaccines | |
IL287985A (en) | A peptide derived from koc1 and a component containing it | |
SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
IL246643B (en) | Preparations and kits for the treatment of immunodeficiency virus/acquired immunodeficiency syndrome | |
SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
ZA201703123B (en) | Combination long acting compositions and methods for hepatitis c | |
GB201508099D0 (en) | Dengue vaccines | |
TH1501007823A (th) | วิธีการเเละองค์ประกอบสำหรับวัคซีนเดงกีไวรัส | |
GB201408046D0 (en) | Virus preparations | |
TH1501005277A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน | |
GB201406470D0 (en) | Virus | |
GB201403582D0 (en) | Virus |